Passage Bio Inc. (PASG)
0.38
0.03 (7.62%)
Apr 01, 2025, 10:37 AM - Market open
7.62% (1D)
| Bid | 0.37 |
| Market Cap | 23.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -66.64M |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -0.35 |
| Forward PE | -1.05 |
| Analyst | Buy |
| Ask | 0.38 |
| Volume | 15,706 |
| Avg. Volume (20D) | 308,418 |
| Open | 0.34 |
| Previous Close | 0.35 |
| Day's Range | 0.34 - 0.38 |
| 52-Week Range | 0.33 - 1.64 |
| Beta | 1.55 |
About PASG
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 28, 2020
Employees 60
Stock Exchange NASDAQ
Ticker Symbol PASG
Website https://www.passagebio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PASG stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 1491.93% from the latest price.
Stock Forecasts5 months ago
+11.4%
Passage Bio shares are trading higher after the co...
Unlock content with
Pro Subscription
